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Abstract Hyperhomocysteinemia and factors of homo-
cysteine metabolism, S-adenosylhomocysteine (AdoHcy)
and S-adenosylmethionine (AdoMet), may play a role in
Alzheimer’s disease (AD). With liquid-chromatography-
tandem-mass-spectrometry AdoMet and AdoHcy were
determined in brains of 8- and 15-month-old APP/PS1
Alzheimer mice, and their possible roles in AD brains
investigated. The ﬁnding that AdoMet levels do not differ
between the genotypes in (young) 8-month-old mice, but
are different in (older) 15-month-old APP/PS1 mice com-
pared to their wild-type littermates, suggests that altera-
tions in AdoMet are a consequence of AD pathology rather
than a cause. During aging, AdoMet levels decreased in the
brains of wild-type mice, whereas AdoHcy levels dimin-
ished in both wild type and APP/PS1 mice. The ﬁnding that
AdoMet levels in APP/PS1 mice are not decreased during
aging (in contrast to wild-type mice), is probably related to
less demand due to neurodegeneration. No effect of the
omega-3 fatty acid docosahexaenoic acid (DHA) or
cholesterol-enriched diets on AdoMet or AdoHcy levels
were found.
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Introduction
The most pronounced pathological features in the human
Alzheimer (AD) brain are amyloid-b (Ab) depositions,
intracellular tangles, and neurodegeneration. Although the
cause of the disease is largely unknown, the Ab protein is
seen as one of the major contributors [31].
Ab is produced by cleavage of the amyloid precursor
protein (APP) by the b and c secretases, BACE, and
Presenilin (PS). Missense mutations in either APP or the
c-secretase complex (PS1 and PS2), cause overproduction
of Ab, and early onset AD. Early onset AD represents only
5% of all AD cases and therefore explains only a small part
of the cause of the disease. In addition, many studies show
that Ab depositions do not correlate well with neuronal
damage and cognitive decline. Therefore, it is suggested
that beside Ab, other risk factors play an important role in
the development of AD. Nowadays, more and more con-
sensus is reached about vascular disorders being major risk
factors for AD. Hyperhomocysteinemia for example, was
until recently believed to be a risk factor for cardiovascular
disorders [23] and associated with an increased risk of AD
[20, 28]. It could therefore be suggested that hyperhomo-
cysteinemia, cardiovascular disorders, and AD are inter-
related with each other. However, this is currently under
debate because of recent homocysteine-lowering interven-
tion studies, showing no relation between cardiovascular
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unclear whether lowering of homocysteine (Hcy) by folic
acid intake, can diminish AD prevalence or improve cog-
nition [5, 21], because recent large randomized Hcy low-
ering intervention trials did not show beneﬁcial effect of
lowering Hcy with folate and vitamin B12 on cognitive
function [21]. Among others, we therefore suggest that
hyperhomocysteinemia itself is not causing AD, and that
other factors of the Hcy metabolism, such as S-adenosyl-
homocysteine (AdoHcy) and S-adenosylmethionine (Ado-
Met), probably play a more important role in vascular
disease [17] and AD development [2, 24, 32].
AdoMet is a biological methyl donor and is a product of
the conversion of methionine and ATP. Transfer of the
methylgroup from AdoMet leads to the formation of Ado-
Hcy which in turn inhibits cellular methylation. Methyla-
tion is required in many essential biological processes, such
as gene expression, regulation of protein function, and
neurotransmitter synthesis, and altered methylation patterns
might play a role in AD [2, 24, 32]. Subsequently, AdoHcy
can be hydrolyzed to Hcy and adenosine by AdoHcy
hydrolase. However, it is important to mention that this
hydrolysis is a reversible reaction that favors the synthesis
of AdoHcy. In vivo, the reaction proceeds in the direction of
hydrolysis only if the products, adenosine and Hcy, are
removed rapidly [6, 18, 22].
Indeed, there are studies showing a role for AdoMet and
AdoHcy in AD [2, 24, 30]. It is suggested that DNA
methylation for example, is involved in APP processing
and Ab production through the regulation of Presenilin1
(PS1) expression. For example, AdoMet administration in
human neuroblastoma cells down regulates PS1 gene
expression and Ab production [30]. Other studies from the
same group showed that alteration in AdoMet/Hcy cycle
(due to reduction of folate and vitamin B12 [10]o r
deprivation of folate and vitamin B12 and B6 [8, 9])
deregulates b and c-secretases expression and Ab produc-
tion in both neuroblastoma cells and TgCRND8 Alzheimer
mice [8–10].
Other studies have shown decreased AdoMet and Ado-
Hcy levels in the cerebrospinal ﬂuid (CSF) of AD patients
compared to age-matched healthy volunteers [2, 24].
Until now, most studies determined AdoMet and Ado-
Hcy levels in CSF of AD patients [3]. However, AdoMet
and AdoHcy remain mostly intracellular and do not pass
membranes easily, and it could therefore be possible that
AdoMet and AdoHcy levels in brain tissue comprise a
more reliable reﬂection of AD processes than CSF or
serum levels which are a 100-fold lower.
There is only one study describing severely decreased
AdoMet levels in brain tissue of AD patients [24].
Although the authors carefully matched with respect to
postmortem time the results of this study might be difﬁcult
to interpret, since AdoMet levels decrease with more than
60% and AdoHcy levels increase with 80% within 15 h
after death [25]. In addition, it is still unknown whether
alterations in AdoMet and AdoHcy levels are cause or
consequence of AD pathology.
In order to further investigate the role of AdoMet and
AdoHcy in AD development we determined AdoMet and
AdoHcy levels in brain tissue of 8- and 15-month-old wild
type and APP/PS1 double transgenic Alzheimer mice.
These two ages were chosen because in young (8-month-
old) mice no neurodegeneration, almost no cognitive
impairment, and very low levels of Ab are present, whereas
in old APP/PS1 mice (15-month-old) neurodegeneration in
the hippocampus becomes clear, and cognitive impairment
and Ab deposition are quite severe [16].
In addition, we investigated the effect of aging and the
effects of cholesterol- and the omega-3 fatty acid docosa-
hexanoic acid (DHA) containing diets on AdoMet and
AdoHcy levels. These nutritional components inﬂuence
vascular health [11, 13, 14, 26] and the risk of developing
AD [7, 15, 29]. In our previous studies we showed that
long-term dietary interventions with cholesterol and or
DHA also changed AD-like pathology and vascular factors
in 8-and 15-month-old APP/PS1 mice. AdoMet and Ado-
Hcy might also inﬂuence AD like pathology and vascular
health [16] and it could be hypothesized that the above-
mentioned nutritional components may inﬂuence and
AdoMet and AdoHcy levels as well.
Materials and methods
Animals and diets
The APPswe/PS1dE9 founders were obtained from Johns
Hopkins University, Baltimore, MD, USA (D. Borchelt and
J. Jankowsky, Dept. of Pathology), and a breeding colony
was established at the Radboud University Nijmegen
Medical Centre, The Netherlands. Male APP/PS1 trans-
genic mice and their wild-type littermates were randomly
assigned to different diet groups. The number of animals
per group was decided on the basis of availability. The
experimental diets differed with respect to the composition
of the 5% fat in the diets [15] but are all isocaloric. Feeding
the diets started at 2 months of age.
Transgenic mice and their wild-type littermates were fed
either a Typical Western Diet (TWD), containing 1%
cholesterol, a high percentage of saturated fatty acids
(SFA = 53%), and long chain poly unsaturated fatty acid
(LCPUFA) ratio of n6/n3 = 22.5, or a DHA diet contain-
ing 0.4% DHA, a low percentage SFA (20%), and a
LCPUFA ratio of n6/n3 = 2.5, or a standard control diet
(STD), with 38% SFA and LCPUFA ratio of n6/n3 = 7.5.
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number of mice used in each experiment. The mice were
selected upon availability from another existing study
performed in our own lab (submitted). Throughout the
experiments the animals were housed individually in a
controlled environment (the mice were housed in the cen-
tral animal facility with the temperature controlled at 21C,
and an artiﬁcial 12:12 h light:dark cycle (lights on at 07.00
am)), with some cage enrichment, consisting of an Iglo and
some nesting material. Food and water were available
ad libitum. The experiments were performed according to
Dutch regulations of the Animal Experimentation Act and
the EC Directive 86/609 and were ethically approved by
the Ethical Review Committee of the Radboud University
Nijmegen Medical Centre.
Brain sample collection and storage
Directly following anesthesia with Nembutal (60 mg/kg,
i.p.) (Ceva Santa Animals BV, Maassluis), all mice were
weighed and thereafter decapitated and the brains were
removed from the skull. The entire brain, without the spinal
cord was thereafter dissected into three smaller pieces, of
which the frontal part of the brain was used for this
experiment. All pieces were snap-frozen in liquid nitrogen
and were kept frozen at -80C until further processing.
A 40-mg tissue piece, containing the frontal part of the
brain was prepared by soniﬁcation in 800 ll cold PBS, and
thereafter centrifuged at 4C at 14,000 rpm for 5 min. The
supernatant was removed and diluted eight times. One part
was used for HPLC tandem MS measurements, and another
part for determination of the protein amount in the sample
using the Lowry method [27].
S-adenosylmethionine (AdoMet)
and S-adenosylhomocysteine (AdoHcy) measurements
As previously described by Gellekink et al. [12], AdoMet
and AdoHcy levels in brain tissue were measured using
liquid chromatography tandem mass spectrometry (LC-
MS/MS).
In short, after addition of the internal standards AdoMet-
d3 and AdoHcy-d5 to the pretreated tissue sample (see
above), solid phase extraction (SPE) columns containing
phenyl boronic acid (PBA) were used to bind AdoMet and
AdoHcy and their internal standards and to deproteinize the
samples. AdoMet and AdoHcy were eluted in 0.1 N formic
acid and measured with the LC tandem mass spectrometer
(MS/MS) (Quatro LC from Micromass), in the positive-ion
mode.
Statistics
Linear regression analysis was used to verify the linearity
of the calibration curves. In order to analyze the possible
differences between the two genotypes and the different
diet groups a Multivariate ANOVA was conducted with the
between group factors diet and genotype. In order to
investigate effects of aging in the two different genotypes a
Multivariate ANOVA was used with the between group
factors age and genotype.
Results
No changes in bodyweight were found between the geno-
types, the two different age groups or diet groups.
Genotype effects
No changes in AdoMet and AdoHcy levels, and conse-
quently in the ratio between AdoMet and AdoHcy levels
(methylation index), were observed between 8-month-old
wild type and APP/PS1 mice (Fig. 1a–c). In addition, also
in 15-month-old mice no changes were observed in Ado-
Hcy levels between the genotypes (Fig. 1b). However, we
did observe a signiﬁcant decrease in AdoMet levels in 15-
month-old wild-type mice compared to APP/PS1 mice
(Fig. 1a; F(1,45) = 7.54, p\0.01). Consequently, the
AdoMet/AdoHcy ratio is increased in the APP/PS1 mice
(Fig. 1c; ((1,45) = 7.17, p\0.01).
Aging effects
AdoHcy levels signiﬁcantly decrease during aging in both
wild-type and APP/PS1 mice (F(1,79) = 9.50, p\0.01).
Due to an interaction between genotype and age in AdoMet
levels and the ratio between AdoMet and AdoHcy levels
(methylation index), the effects of aging in wild type and
APP/PS1 mice were determined separately for these
parameters.
Table 1 Number of male mice used in each diet group
Groups 8-month-old (n) 15-month-old (n)
STD (wt) 5 10
STD (tg) 6 8
TWD (wt) 6 9
TWD (tg) 6 8
DHA (wt) 5 9
DHA (tg) 7 3
STD standard diet, TWD Typical Western Diet, containing 1% cho-
lesterol, DHA docosahexanoic acid diet, containing 0.4% of DHA. Wt
wild-type mice, Tg transgenic APP/PS1 mice
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was only found in wild-type mice (F(1,42) = 8.09,
p\0.01) and not in APP/PS1 mice.
Thus, AdoHcy decreased in both wild type and APP/PS1
mice during aging, whereas AdoMet only decreased in
wild-type mice. Consequently, the AdoMet/AdoHcy ratio
(methylation index) in wild-type mice did not alter due to
aging, but was signiﬁcantly increased in APP/PS1 mice
with aging (Fig. 1f; F(1,36) = 6.61, p = 0.01).
Diet effects
Neither a cholesterol- nor a DHA-containing diet did alter
AdoMet or AdoHcy levels in brain tissue of 8- and 15-
month-old APP/PS1 and wild-type mice as compared to the
standard diet (data not shown).
Discussion
In this study we showed that AdoMet tissue levels did not
differ between 8-month-old APP/PS1 mice and wild-type
littermates, but are decreased in 15-month-old wild-type
mice compared to APP/PS1 mice. Moreover, tissue levels
of AdoHcy decreased in both wild type and APP/PS1 mice
during aging, whereas AdoMet only decreases in wild-type
mice. Because AdoMet and AdoHcy brain levels in
(young) 8-month-old mice are unchanged, in contrast to the
(old) 15-month-old mice, these results indicate that alter-
ations in AdoMet may be a consequence of AD-like
pathology in the APP/PS1 mice rather than a cause. In
addition, we showed that cholesterol-containing, or DHA-
enriched diets did not affect AdoMet or AdoHcy levels in
brain tissue of APP/PS1 and wild-type mice.
This is the ﬁrst study describing AdoMet and AdoHcy
levels in brain tissue of aging mice. Stramentinoli et al.
found decreased AdoMet levels in brain tissue of aging rats
[33]. In addition they measured the synthesis of AdoMet by
adenosyl transferase and AdoMet utilization by COMT,
and concluded that the decrease in AdoMet levels was a
consequence of increased utilization during aging. The
decrease in AdoMet and AdoHcy found in our wild-type
mice could also be the consequence of increased utiliza-
tion. It could be suggested that AdoMet levels in the brain
tissue of the APP/PS1 mice, used in this study, do not
decrease during aging because of less demand caused by
neurodegeneration. This seems to be conﬁrmed by the
hippocampal atrophy and increased Ab deposition we
observed in the hippocampus and frontal cortex of the 15-
month-old APP/PS1 mice compared to 8-month-old APP/
PS1 mice [16]. If the above-mentioned hypothesis is valid,
and AdoMet remains unaltered in aged APP/PS1 mice
compared to young APP/PS1 mice, because of less demand
for methylation due to neurodegeneration, AdoHcy levels
Fig. 1 Levels of S-adensylmethionine (AdoMet; a, d) and S-adeno-
sylhomocysteine (AdoHcy; b, e) and the methylation index (AdoMet/
AdoHcy; c, f) in brain tissue of 8- and 15-month-old APP/PS1 mice
and their wild-type littermates. 8-month-old wild-type mice n = 16,
8-month-old APP/PS1 mice n = 19 15-month-old wild-type mice
n = 28, 15-month-old APP/PS1 mice n = 19. Values represent mean
and SEM. * p\0.01
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Indeed, AdoHcy levels are similar in the 15-month-old
wild-type mice and APP/PS1 mice. In Fig. 2, the above-
mentioned ﬁndings and hypothesis are schematically
depicted.
Although we have hypothesized that AdoMet levels
remain high because of less demand due to neurodegener-
ation, we do not have proof for that yet. Because of the
complexity of factors that are involved in AdoMet metab-
olism in AD, other factors in the methylation cycle or for
example oxidative stress, could be involved and should be
investigated before we can validate our statement. Bernardo
shows [1] that 16–18-month-old Tg2576 AD mice have
higher Hcy levels than wild-type mice. This could have
explained the high-AdoMet levels; however, the AdoMet
levels in the 8-month-old APP/PS1 mice in our study,
should have been increased compared to 8-month-old wild
types, and that was not the case. In addition, high Hcy levels
are known to inhibit AdoHcy hydrolase, which results in
increase in AdoHcy levels [32], and therefore higher Ado-
Hcy levels would have been expected in our APP/PS1 mice
compared to wild types which was also not the case.
The ﬁnding that AdoMet levels signiﬁcantly differ only
in 15-month-old APP/PS1 mice compared to their wild-
type littermates, but not in 8-month-old mice, also indicates
that alterations in AdoMet levels are a consequence of AD
pathology rather than a cause. The difference in AdoMet
levels between wild type and AD mice is also found by
Fuso et al. [9]. They show a concentration of 158 nmol/g
AdoMet in TgCRND8 mice compared to 52 nmol/g Ado-
Met in their control mice. It could be argued that these
mice are much younger and should not be compared with
our mice; however, the 3-month-old TgCRND8 animals
show early and age-related Ab deposition and cognitive
impairment what is comparable to our 15-month-old APP/
PS1 mice. In contrast, our 8-month-old APP/PS1 mice
show almost no Ab plaque deposition and very mild cog-
nitive impairment.
The ﬁnding that cholesterol- or DHA-containing diets
do not alter AdoMet or AdoHcy levels in brain tissue of
either wild type or APP/PS1 mice, but in contrast do have
effects on AD pathology and cerebral hemodynamics [7,
15, 29], suggests that cholesterol- or DHA-containing diets
do not inﬂuence cerebral hemodynamics or AD pathology
via the methylation cycle. Thus, AdoMet and AdoHcy are
no important key players in the mechanisms explaining the
effects of cholesterol and DHA in AD pathology.
Main conclusions
We measured AdoMet and AdoHcy levels in brain tissue of
8- and 15-month-old wild type and APP/PS1 mice, to
investigate whether there is a role for these metabolites of
methylation in the AD brain. The ﬁnding that AdoMet
levels do not differ between the genotypes in (young) 8-
month-old mice, but do differ in (older) 15-month-old
APP/PS1 mice compared to their wild type littermates,
Wt mice
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O-methyl transferase (COMT)
Increased utilization of 
AdoMet and AdoHcy
AdoMet and AdoHcy levels 
decrease
APP/PS1 Alzheimer mice
Alzheimer pathology like Neuro-
degeneration and Aβ deposition.
Less demand for methylation 
because of less viable cells
AdoHcy levels decrease and 
 AdoMet levels remain 
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a
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i
n
g
a
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n
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aging
Nett effect: 
AdoMet levels significantly higher in aged Alzheimer  mice compared to
aged wildtype mice. 
AdoHcy levels decrease in both wildtype and APP/PS1 mice during aging 
Fig. 2 Concept model of the
hypothetical effects of aging on
S-adensylmethionine (AdoMet)
and S-adenosylhomocysteine
(AdoHcy) levels in wild type
and APP/PS1 mice
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AD pathology rather than a cause, and it could be sug-
gested that it is the result of neurodegeneration during
aging (Fig. 2). However, because of a lack of brain tissue
we only measured AdoMet and AdoHcy levels in this
experiment. It would, however, be of great value to mea-
sure more components of the methylation cycle in future
studies to validate our conclusions.
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